Insulin Lispro

Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology and the first commercially available insulin analog. It differs from human insulin by a B28(Pro→Lys)/B29(Lys→Pro) transposition — replacing proline at B28 with lysine and lysine at B29 with proline. This swap breaks the hydrophobic surface that drives self-association: regular human insulin forms stable hexamers in pharmaceutical solution that must dissociate to monomers before subcutaneous absorption, whereas lispro exists predominantly as monomers and dimers, enabling far faster absorption.

Mechanism of Action

Insulin lispro has the same physiological effects as endogenous insulin:

• Cellular glucose uptake: binds to insulin receptors on muscle and fat cells, facilitating glucose entry.
• Hepatic effects: suppresses glycogenolysis and gluconeogenesis, reducing hepatic glucose output.
• Glycogen synthesis: promotes glucose storage in liver and muscle.
• Lipid metabolism: inhibits lipolysis and ketone production.
• Protein metabolism: increases amino acid uptake and protein synthesis.

Pharmacokinetics

Parameter	Insulin Lispro	Regular Human Insulin
Onset of action	10–15 minutes	30–60 minutes
Peak effect	30–90 minutes	2–4 hours
Duration	3–5 hours	6–8 hours

The rapid onset and shorter duration allow administration immediately before, during, or shortly after meals — providing better postprandial glucose control and greater mealtime flexibility than regular human insulin.

• Bioavailability: 55–77% after subcutaneous administration (dose-dependent).
• Volume of distribution: dose-dependent. At 0.1 U/kg SC: 1.55 L/kg; at 0.2 U/kg SC: 0.72 L/kg. IV Vd: 0.13 L/kg.
• Protein binding: not applicable — insulin does not bind plasma proteins at therapeutic concentrations.
• Metabolism: degraded by insulin-degrading enzyme (IDE) in liver, kidney, and muscle; no active metabolites. Animal-model data show distribution to liver and kidney as primary degradation sites; comprehensive human metabolite profiling is limited.
• Half-life: approximately 1 hour (subcutaneous); shorter than regular insulin (~1.5 h SC). IV half-life approximately 0.85–0.92 hours.
• Clearance: 21.0 mL/min/kg at 0.1 U/kg dose; 9.6 mL/min/kg at 0.2 U/kg dose (dose-dependent non-linear clearance).
• Excretion: renal elimination of degradation products.

• Postprandial glucose control: superior to regular insulin, with 20–40 mg/dL lower postprandial glucose excursions and smoother daily glucose profiles.
• HbA1c: comparable or slightly better reduction versus regular insulin in basal-bolus regimens.
• Hypoglycemia: similar or lower overall rates compared to regular insulin; nocturnal hypoglycemia reduced by 30–50%.
• Insulin pump use: well-suited for continuous subcutaneous insulin infusion (CSII) due to stable pharmacokinetics.

• Type 1 diabetes mellitus: as part of a basal-bolus regimen, for insulin pump therapy, and for correction of hyperglycemia.
• Type 2 diabetes mellitus: when mealtime insulin therapy is required, in combination with basal insulin or oral antidiabetic medications.
• Gestational diabetes: when diet and exercise are insufficient.
• Acute settings: diabetic ketoacidosis (intravenous administration), hyperglycemic emergencies, perioperative glucose management, critical care.

Approved for use in adults, adolescents, and children.

• Hypersensitivity to insulin lispro or any of the excipients.
• Active hypoglycemia: do not administer during hypoglycemic episodes.

Use with caution / dose adjustments required: renal or hepatic impairment, acute illness, changes in physical activity, changes in diet.

Very Common: hypoglycemia — the most common adverse effect. Symptoms range from shakiness, sweating, hunger, and palpitations to confusion, seizures, or loss of consciousness in severe cases.

Common (1–10%): injection site reactions (lipohypertrophy, lipoatrophy, redness, swelling, itching, pain), weight gain (typically 2–4 kg with intensive therapy), edema (especially when initiating or intensifying insulin).

Uncommon (<1%): local or systemic allergic reactions, anaphylaxis (very rare), hypokalemia, sodium retention.

Rare: insulin antibodies (usually clinically insignificant), transient visual disturbances due to changes in glucose control affecting lens hydration.

Drugs that increase hypoglycemia risk: oral antidiabetic medications, ACE inhibitors, fibrates, fluoxetine, MAO inhibitors, high-dose salicylates, sulfonamide antibiotics, alcohol.

Drugs that decrease insulin effect: corticosteroids, thiazide diuretics, thyroid hormones, growth hormone, sympathomimetics, danazol, atypical antipsychotics.

Drugs that may alter insulin requirements: beta-blockers (may also mask hypoglycemia symptoms), alcohol (increases hypoglycemia risk, especially fasting), clonidine, lithium salts.

Insulin lispro is administered by subcutaneous injection or continuous subcutaneous infusion (insulin pump). Intravenous administration is reserved for clinical settings such as DKA.

Injection Sites

Abdomen (fastest absorption), thighs, upper arms, and buttocks. Rotate sites within the same anatomic region to prevent lipodystrophy. Maintain at least 1 cm distance between injection points.

Timing

• Inject 0–15 minutes before starting a meal.
• May be administered immediately before, during, or within 20 minutes after starting a meal in certain situations.

Dose Individualization

Total daily insulin requirements typically range from 0.5–1.0 Units/kg/day, varying widely. In a basal-bolus regimen, approximately 50% of the total daily dose is typically given as basal insulin and 50% as prandial insulin (insulin lispro), divided among main meals.

Mealtime dosing methods:

• Carbohydrate counting: e.g., 1 unit per 10–15 g carbohydrate, plus a correction component for elevated glucose.
• Fixed-dose method: consistent carbohydrate intake at meals with a fixed dose at each meal.

Correction doses: based on insulin sensitivity factor — typically 1 unit lowers glucose by 30–50 mg/dL.

Special Populations

• Type 1 diabetes: requires basal-bolus regimen; titrate based on glucose monitoring.
• Type 2 diabetes: often lower initial requirements; may start at ~4 units per meal.
• Renal/hepatic impairment: insulin requirements may decrease; monitor closely.
• Pregnancy: requirements typically increase in 2nd and 3rd trimesters.
• Elderly: may have decreased requirements and higher hypoglycemia risk.
• Children: weight-based dosing with frequent adjustments.

Insulin Pump Use

Approved for continuous subcutaneous insulin infusion. Change infusion site every 2–3 days. Do not mix with other insulins in the pump reservoir.

Mixing with Other Insulins

• May be mixed with NPH insulin: draw insulin lispro first, inject immediately after mixing.
• Do not mix with long-acting analogs (e.g., insulin glargine, insulin detemir, insulin degludec).

Hypoglycemia

• Mild–moderate symptoms (conscious patient): administer 15–20 g fast-acting carbohydrate (glucose tablets, juice, regular soda); recheck glucose in 15 minutes; repeat if needed.
• Severe symptoms (unconscious): administer glucagon by trained person or seek emergency services immediately.
• Prevention: regular glucose monitoring, consistent meal timing, exercise adjustments, glucose source on hand, medical identification.

Sick Day Management

Continue insulin even when not eating. Monitor glucose every 2–4 hours. Check ketones if glucose >240 mg/dL. Stay hydrated. Contact a healthcare provider for persistent high glucose or ketones.

Exercise

Increases insulin sensitivity and glucose uptake — may need dose reduction or extra carbohydrates. Avoid injecting into areas that will be exercised.

Hypoglycemia Unawareness

Some patients lose the ability to recognize hypoglycemia symptoms, especially with long-standing diabetes, frequent hypoglycemia, or intensive therapy. Less stringent glycemic targets and more frequent monitoring are required.

Travel

Carry insulin in hand luggage with prescription/medical letter. Account for time-zone changes. Pack extra insulin and supplies. Keep insulin cool but never frozen.

Pregnancy and Breastfeeding

Insulin is the preferred treatment in pregnancy. Compatible with breastfeeding; monitor glucose as requirements may decrease postpartum.

Effect on Driving

Hypoglycemia can impair the ability to drive safely. Check glucose before driving, carry a glucose source in the vehicle, and pull over if symptoms develop.

Unopened vials/pens: store in a refrigerator at 2–8°C in the original carton. Do not freeze. Protect from heat and light.

Opened vials: may be refrigerated (2–8°C) or kept at room temperature (below 30°C). Use within 28 days.

Opened pens: do not refrigerate after first use; store at room temperature (below 30°C). Use within 28 days. Protect from direct heat and light.

Pump reservoirs: change every 48 hours. Do not expose to temperatures above 37°C.

Never use frozen insulin. Discard if the solution becomes cloudy, thickened, or discolored. Keep out of reach of children.

24 to 36 months unopened, depending on formulation. After opening, 28 days. Do not use after the expiry date.

Prescription required.